HLB fails to win US FDA's approval for Rivoceranib liver cancer drug

Shares of all nine listed affiliates of HLB, a Kosdaq-listed biotech company, plunged on Friday to their daily price floors, as the U.S. Food and Drug Administration (FDA) rejected a new drug approval for Rivoceranib, the Korean firm’s liver cancer treatment.